Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 7236
â€¢human somatic cell nuclear transfer applications for therapeutic purposes and
â€¢the cloning of animals for agricultural purposes, for the production of recombinant proteins, peptides and polypeptides for human transplantation, cells for human transplantation and tissues from human transplantation, but excluding the Licensor's field.
IPSCIO Record ID: 25871
IPSCIO Record ID: 28403
09/736,268 Transfer to De-Differentiate Recipient Cells
IPSCIO Record ID: 28404
By way of example, but not in limitation, Licensee shall have the right to use Licensed Technology within the Field for the following purposes to produce mammalian embryonic stem (ES) cells and to produce from those mammalian embryonic cells, differentiated cells for human therapeutic purposes or for commercial research purposes, including drug screening assays, and to produce pluripotent cells including ES cells, differentiated human cells for human diagnostic and therapeutic purposes and/or for commercial research purposes, including drug screening assays. b) A royalty bearing, twelve (12) month exclusive license in the Territory in the Field to expand in culture, prepare for sale, sell, offer for sale, import and export Act Animal Cell Lines. The twelve-month term of exclusivity granted to Licensee shall begin upon the date of the first sale of the Act Animal Cell Lines. Licensor and Licensee agree that after the twelve-month period of exclusivity has passed, Licensor and Licensee shall negotiate in good faith to establish reasonable minimum sales goals over reasonable evaluation periods in order to maintain Licenseeâ€™s exclusive rights hereunder. If Licensor fails to meet the minimum sales goals then Licenseeâ€™s exclusive rights shall revert to nonexclusive rights.
08/935,052 US 1997-09-22 CICM Cells and Non-Human Mammalian Embryos
6,235,970 2001-05-22 Prepared by Nuclear Transfer of a Proliferating Differentiated Cell or its Nucleus
09/828,876 US 2001-04-10 Cloning Using Donor Nuclei from Differentiated Fetal and Adult Cells UMASS
10/374,512 US 2003-02-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
60/161,987 US 1999-10-28 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
2,387,506 CA 2000-10-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
Declared patent interferences
a) Patent Interference No. 104,746, involving U.S. Patent No. 5,945,577 and U.S. Patent Application No. 09/650,194.
b) Patent Interference No. 105,192, involving U.S. Patent No. 6,235,970 and U.S. Patent Application No. 09/989,126.
Potential patent interferences, verbally threatened to be filed against the following patents
IPSCIO Record ID: 4297
Under the agreement, we agreed by September 1, 2000, to produce at least 20 cloned hSA cows (cows produced with our technology that are transfected with a GTC recombinant DNA construct and contain the hSA transgene and express hSA in their milk for the purpose of transgenic production of milk products.)
IPSCIO Record ID: 26263
5,453,366 Method of Cloning Bovine Embryos
6,011,197 Method of Cloning Bovines Using Reprogrammed Non-mbryonic Bovine Cells
6,258,998 Method of Cloning Porcine Animals
5,843,754 Parthenogenic Bovine Oocyte Activation
5,496,720 Parthenogenic Oocyte Activation
09/573,044 Use of embryonic stem cells as nuclear donors during nuclear transfer and use of said techniques to produce chimeric and transgenic animals.
6,194,202 Parthenogenic Oocyte Activation
6,077,710 Parthenogenic Oocyte Activation
6,107,543 Culture of Totipotent Embryonic Inner Cells Mass Cells and Production of Bovine
IPSCIO Record ID: 802
Cells shall mean in vitro generated, growth factor responsive neural stem cells to the extent claimed in the Patent Rights and shall include all progeny and derivatives of such stem cells (including Progenitor Cells and their progeny and Stem Cells and their progeny) and Cell shall mean one of such cells. An in vitro generated growth factor responsive neural stem cell shall include a neural stem cell, or its derivatives or progeny, which exhibits one or more of the following characteristics
(a) is dependent on the presence of a growth factor for survival and viability, or (b) proliferates or differentiates due to the presence of a growth factor, whether alone or in combination with another biologically active molecule; and
An EGF-responsive neuronal stem cell includes
a neuronal stem cell, or its derivatives or progeny, which exhibits one or more of the following characteristics
(a) is dependent on the presence of EGF for survival and viability, or (b) proliferates or differentiates due to the presence of EGF, whether alone or in combination with another biologically active molecule all to the extent claimed or allowed under the Patent Rights.
Product shall mean any product utilizing the Cells and the manufacture, use, or sale of which, but for the license granted to the Company hereunder, would infringe any claim of the Patent
Services shall mean any use of the Cells or the Cell Technology to perform a service for a third party for compensation, where such use would, but for the license granted to the Company hereunder, infringe any claim of the Patent Rights.
(a) for Cell Replacement Therapy; (b) for the purposes of Transplantation anywhere in the human body for the treatment or prevention of human disease, injury, or disorder; (c) for augmenting the function of endogenous cells by Transplantation or Cell Replacement Therapy; and (d) for the purposes of transplantation therapy in general (e.g., Transplantation of the Cells for delivery of one or more Agents).